#TRLInsights - 1 in 3 participants do not feel valued for their contribution to clinical research. This can impact retention, satisfaction & overall adherence. TransCelerate BioPharma has therefore developed a best practices #Gratitude #Toolkit. 👉 Source: transceleratebiopharmainc.com/assets/patient…

#TRLInsights - According to Tufts Center for the Study of Drug Development, a typical Phase III #clinicaltrial conducted during 2016-2021 included an average of 25.8 endpoints. This number is 37% higher compared to 2015, signalling a sharp increase in clinical trial complexity. Source: csdd.tufts.edu/impact-reports

#TRLInsights - 55% of sponsors & CROs report using RBQM in their #clinicaltrials. 78% trust that #RBQM improves study quality, while 64% believe RBQM increases efficiency & cost savings, and 53% trust it can reduce timelines. Source: csdd.tufts.edu/impact-reports #DeSci #TRL

Community announcement 📢 Dear Triall community, It is with a heavy heart that we must inform you about challenges Triall is facing in light of ongoing economic headwinds. 👉 Read the full message: t.me/triallofficial…

Community announcement 📢 Dear Triall community, Today, we regretfully must inform you that Triall will be closing its business operations. 👇 Read the full message t.me/triallofficial…

MEXC de-listing announcement 📢 In light of Triall’s company closing, $TRL will be de-listed from MEXC on March 2, 2024. Please withdraw your assets in time to avoid any asset losses. 👇 More info on deposits, trading, and withdrawals: mexc.com/support/articl…

LBank de-listing announcement In light of Triall’s company closing, $TRL will be de-listed from LBank.com at 12:00 UTC on March 4, 2024. Please cancel your pending orders. For those who do not actively cancel, LBank will cancel them uniformly. support.lbank.com/hc/en-gb/artic…